All In Biotech

BLA 125545 · Hospira INC

Retacrit

Epoetin Alfa-Epbx · Injection

Last checked: Nov 20, 2026Latest source record: Jun 4, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

May 15, 2018

Approved uses

2

Original approval plus efficacy supplements

Registered trials

593

243 Phase 3, 14 recruiting

FAERS reports

2,244

1,516 serious, 494 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE WARNING: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE See full prescribing information for complete boxed warning. Chronic Kidney Disease: • In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL ( 5.1 ). • No trial has identified a hemoglobin target level, ESA dose, or dosing strategy that does not increase these risks ( 2.2 ). • Use the lowest RETACRIT dose sufficient to reduce the need for red blood cell (RBC) transfusions ( 5.1 ). Cancer: •...

What it is approved for

From the label in effect Jun 22, 2025.

RETACRIT is an erythropoiesis-stimulating agent (ESA) indicated for: • Treatment of anemia due to o Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis ( 1.1 ). o Zidovudine in patients with Human Immunodeficiency Virus (HIV) infection ( 1.2 ). o The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy ( 1.3 ). • Reduction of allogeneic red blood cell (RBC) transfusions in patients undergoing elective, noncardiac, nonvascular surgery ( 1.4 ). Limitations of Use RETACRIT has not been shown to improve quality of life, fatigue, or patient well-being ( 1.5 ). RETACRIT is not indicated for use: • In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy ( 1.5 ). • In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure ( 1.5 ). • In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion ( 1.5 ). • In patients scheduled for surgery who are willing to donate autologous blood ( 1.5 ). • In patients undergoing cardiac or vascular surgery ( 1.5 ). • As a substitute for RBC transfusions in patients who require immediate correction of anemia ( 1.5 ). 1.1 Anemia Due to Chronic Kidney Disease RETACRIT is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and not on dialysis to decrease the need for red blood cell (RBC) transfusion. 1.2 Anemia Due to Zidovudine in Patients with HIV Infection RETACRIT is indicated for the treatment of anemia due to zidovudine administered at ≤ 4,200 mg/week in patients with HIV infection with...

Mechanism: Epoetin alfa products stimulate erythropoiesis by the same mechanism as endogenous erythropoietin.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 30, 2020 Supplement 5 · Efficacy LabelLetter
  • May 15, 2018 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
5 products under this application
  • RETACRIT · EPOETIN ALFA-EPBX 40,000UNITS/ML · INJECTABLE, INJECTION · Prescription
  • RETACRIT · EPOETIN ALFA-EPBX 4,000UNITS/ML · INJECTABLE, INJECTION · Prescription
  • RETACRIT · EPOETIN ALFA-EPBX 2,000UNITS/ML · INJECTABLE, INJECTION · Prescription
  • RETACRIT · EPOETIN ALFA-EPBX 10,000UNITS/ML · INJECTABLE, INJECTION · Prescription
  • RETACRIT · EPOETIN ALFA-EPBX 3,000UNITS/ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Epoetin Alfa" as an intervention, any sponsor and status, largest first.

All 593 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death416
  • off label use329
  • haemoglobin decreased167
  • anaemia109
  • asthenia85
  • diarrhoea80
  • fatigue78
  • hospitalisation73
  • product dose omission issue61
  • nausea58
  • pneumonia58
  • malaise54

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20081
20092
20104
20117
20128
201314
201413
20162
20176
201839
2019151
2020349
2021327
2022381
2023402
2024199
2025166
2026173

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Retacrit (Epoetin Alfa-Epbx)

2024 spending

$27.1M

Beneficiaries

13,155

47,809 claims

Per beneficiary

$2,062

$205.99 per unit

View as table
YearSpending
2020$23,796,443
2021$31,828,561
2022$32,855,063
2023$24,529,471
2024$27,125,959

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 345 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.